The impact of Brexit on the British advanced therapeutic research sector with Matthew Durdy, CGTC
We held a short interview with Matthew Durdy (Chief Business Officer, Cell & Gene Therapy Catapult) at our Phacilitate Leaders Forum to ask his thoughts on the impact of Brexit on the British Biotech sector.

 

Interview at Phacilitate Leaders Forum 2017 with William Podd, Landmark Capital Corporation
As Phacilitate prepares to launch our Investment in Advanced Therapies Summit (London, 3rd May), we caught up with Bill Podd (Founder, President and CEO, Landmark Capital) on what are the challenges in early stage investment for the biotech industry.

 

Discussing Investment and funding with Stephen Potter, Chief Business Officer, AGTC and William Podd, Founder, President and CEO, Landmark Capital/Landmark Angels

 

Read the latest interviews:

Interview with: Ali Mortazavi, CEO, Silence Therapeutics

Interview with: Dr John Beadle, Founding CEO, PsiOxus Therapeutics

Interview with: Vincent BrichardLife Science Partners